Navigation Links
ALung Secures $2.5 Million
Date:10/6/2009

PITTSBURGH, Oct. 6 /PRNewswire/ -- ALung Technologies, Inc. today announced that the company has raised $2.5 million from a group of current ALung investors. The investment will allow the company to fund its Indian and German clinical trials as well as support working capital needs. ALung is the leading developer of a device designed to replace or supplement ventilators in hospitals. The company's Hemolung device is expected to positively impact clinical outcomes and reduce the length of hospital stays by several days, resulting in a significant reduction of total medical costs for providers and insurers.

The Hemolung System is designed to remove carbon dioxide and deliver oxygen directly to the patient's blood via a small catheter, inserted into the jugular or femoral vein, similar to acute kidney dialysis. This treatment is expected to provide a significant benefit over intubation and mechanical ventilation, in that it will allow the patient to talk and eat, and avoid sedation, while giving the lungs the opportunity to heal.

"ALung has the potential to improve care greatly for the target patient group over the current methods used in Intensive Care Units (ICUs), achieving both improvements in clinical outcomes and major savings in cost of care," said Peter M. DeComo, ALung's Chairman and CEO and an investor in the company. "Today's health care community is focused on the principal goals of reducing health care costs and improving patient care. Our device - which can eliminate a very large expenditure of money and human resources while improving outcomes for patients - will therefore be extremely relevant."

Currently 450,000 patients in the U.S. are ventilated each year for temporary, acute or acute-on-chronic respiratory failure. It is anticipated that the clinical trials will demonstrate that the Hemolung System can replace or supplement this form of ventilation. With intensive care unit (ICU) care estimated at $5-7,000 per day, Hemolung is expected to reduce hospital costs through its ability to reduce ICU length of stay. Further cost savings are expected to be realized through the elimination of sedation costs and a reduction in adverse outcomes such as ventilator acquired pneumonia (VAP) - estimated at greater than $125,000 per incident. VAP represents the most common and deadly hospital acquired condition (HAC) with approximately 25 percent of all ventilator patients developing the condition. (ref: Society of Critical Care Medicine).

"We are very enthusiastic regarding the positive outcome of our near-term clinical trials," said Mr. Nick Kuhn, Chief Operating Officer of ALung, "The completion of our eight animal studies, as well as our in vitro testing, have resulted in excellent results, indicating that the upcoming Hemolung human clinical trials should yield very positive results."

ALung is moving forward with a five patient "First in Man" trial in India on the Hemolung

System, and a 20 patient pilot trial in Germany. Both trials are expected to begin in the fourth quarter of 2009.

About ALung Technologies

ALung Technologies, Inc. is commercializing artificial lung devices for the treatment of acute and chronic respiratory disorders. The company's Hemolung System, designed to replace or supplement the use of ventilators for patients with acute respiratory failure, is scheduled to begin clinical trials in the fall of 2009. Learn more about ALung and Hemolung at www.alung.com.

SOURCE ALung Technologies, Inc.


'/>"/>
SOURCE ALung Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials
2. Alexion Secures U.S. Patent for ALXN6000, a First-In-Class Anti-CD200 Monoclonal Antibody
3. GeoVax Secures $10 Million Financing Commitment
4. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
5. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
6. Blue Shield of California Awards $29.6 Million in Pay-for-Performance Programs in 2009
7. Misonix, Inc. Announces the Sale of Sonora Medical Systems for $8 Million
8. Catalyst Pharmaceutical Partners, Inc. To Raise $3.97 Million In Registered Direct Offering
9. SyntheMed Completes $1.0 Million Equity Placement
10. CVS Caremark Launches Distribution of $3 million in Free Seasonal Flu Shot Vouchers to the Unemployed
11. ThermalTherapeutic Systems Completes $2.75 Million Series A Financing With Originate Ventures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... DIEGO , Sept. 22, 2017 AVACEN ... medical device is now successfully helping those with the ... Fibromyalgia diagnosed Amanda in Essex, ... dressed and washing my hair, experiencing no sleep at ... in painful spasm… I cannot recommend [the AVACEN 100] ...
(Date:9/18/2017)... ALLENTOWN , Pa. and KALAMAZOO, Mich. ... Allentown, Penn. , and OptiMed Specialty Pharmacy ... a business partnership to offer a strategic hub service ... PMD Healthcare,s highly sought-after personal spirometer, Spiro PD 2.0, ... A spirometer is a medical device used ...
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017 /PRNewswire/ ... ratings for global supply chains, has published the first annual edition of ... performance of more than 20,400 companies evaluated by EcoVadis, based on Scorecard ... and 2016. ... Global CSR Risk & Performance Index ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... , ... Many families have long-term insurance that covers care for a family ... for care if the client has a cognitive impairment diagnosis. , “What this ... often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, owner ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/13/2017)... ... ... On The Brink”: the Christian history of the United States and the loss of ... William Nowers. Captain Nowers and his wife, Millie, have six children, ten grandchildren, ... Navy. Following his career as a naval aviator and carrier pilot, he spent ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
Breaking Medicine News(10 mins):